NICE· @NICEComms · X·· 13 天前精选AI 评分62
AI 导读
NICE 推荐 Enhertu 用于 HER2-low 晚期乳腺癌，约 1000 名患者可在 NHS 常规使用中接受该药。NICE 表示，此前该药未获常规报销，此次推荐后相关患者可通过 NHS 获得。更多信息见 NICE 官网。
推荐理由
NICE 将 Enhertu 纳入 NHS 常规使用，读者可据此了解 HER2-low 晚期乳腺癌的报销准入范围。
正文
NICE recommends Enhertu for people with HER2-low advanced breast cancer.
Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.
Learn more: https://www.nice.org.uk/news/articles/nice-recommends-enhertu-for-people-with-her2-low-advanced-breast-cancer?utm_medium=organic&utm_source=x&utm_campaign=enhertu170926
来源：NICE · x.com